FDG-PET Imaging of Dementia and Neurodegenerative Disease

Atman Dave, Neil Hansen, Ryan Downey, Craig Johnson

Research output: Contribution to journalArticlepeer-review

Abstract

Dementia syndromes present a diagnostic challenge given their overlapping clinical features and insidious presentations. Cerebral 2-deoxy-2-[F-18]fluoroglucose (FDG) positron emission tomography (PET) is a functional imaging modality commonly used in the evaluation of dementia. While its role in the clinical assessment of dementia is evolving, FDG PET allows for qualitative and quantitative characterization of major dementia syndromes and variants by means of detecting distinct patterns of cortical hypometabolism. Familiarity with these “metabolic signatures” in dementia syndromes can be helpful when interpreting cerebral FDG PET.

Original languageEnglish (US)
Pages (from-to)562-571
Number of pages10
JournalSeminars in Ultrasound, CT and MRI
Volume41
Issue number6
DOIs
StatePublished - Dec 2020

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'FDG-PET Imaging of Dementia and Neurodegenerative Disease'. Together they form a unique fingerprint.

Cite this